NanoString Technologies, Inc.
NanoString Technologies, Inc. (NSTG) Stock Overview
Explore NanoString Technologies, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
5.1M
P/E Ratio
-0.03
EPS (TTM)
$-3.53
ROE
-1.43%
NSTG Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of NanoString Technologies, Inc. (NSTG) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.09.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.03 and a market capitalization of 5.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
R. Bradley Gray
550
530 Fairview Avenue North, Seattle, WA
2013